CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- PositionCurrent ratio is 25.05×, higher than 95% of its Biotechnology peers (median 5.96×)
- FinancialsAltman Z-Score -1.08: distress zone
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
425.58MUSDvs all stocks (USD)
Revenue (TTM)
54.53MUSDvs all stocks (USD)
Profit Margin
-80.68%vs Biotechnology peers
Beta
-0.3310xvs all stocks
52-Week Change
-15.06%vs all stocks
Market Capitalization
425.58MUSDvs all stocks (USD)
Enterprise Value
144.38MUSDvs all stocks (USD)
Forward P/E
-5.45xvs Biotechnology peers
Price to Sales (TTM)
7.80xvs Biotechnology peers
Price to Book (MRQ)
1.50xvs Biotechnology peers
Enterprise to Revenue
2.65xvs Biotechnology peers
Enterprise to EBITDA
-2.44xvs Biotechnology peers
Profit Margin
-80.68%vs Biotechnology peers
Operating Margin
-1850.20%vs Biotechnology peers
Return on Assets (TTM)
-10.67%vs Biotechnology peers
Return on Equity (TTM)
-14.39%vs Biotechnology peers
Revenue (TTM)
54.53MUSDvs all stocks (USD)
Revenue per Share (TTM)
1.02USDUpdated Sep 28, 2026Quarterly Revenue Growth
-77.10%vs Biotechnology peers
Gross Profit (TTM)
-10.42MUSDvs all stocks (USD)
EBITDA (TTM)
-59.04MUSDvs all stocks (USD)
Net Income (TTM)
-43.99MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
-77.15%vs Biotechnology peers
Operating Cash Flow (TTM)
-60.05MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-54.22MUSDvs all stocks (USD)
Payout Ratio
0.00%vs Biotechnology peers
Revenue
9.68MUSDFY2025 · Dec 31, 2025Operating Income
-184.56MUSDvs all stocks (USD)
Pre-tax Income
-200.83MUSDFY2025 · Dec 31, 2025Income Tax Expense
43.26MUSDFY2025 · Dec 31, 2025Net Income
-244.09MUSDFY2025 · Dec 31, 2025EBIT
-184.56MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-153.26MUSDFY2025 · Dec 31, 2025Research & Development
134.85MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
59.39MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
14.14MUSDFY2025 · Dec 31, 2025EPS (Basic)
-4.53USDFY2025 · Dec 31, 2025EPS (Diluted)
-4.53USDFY2025 · Dec 31, 2025Basic Shares Outstanding
53.83MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
53.83MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-244.09MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-174.31MUSDFY2025 · Dec 31, 2025Free Cash Flow
-174.45MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
308.39MUSDFY2025 · Dec 31, 2025Income Tax Paid
931.00KUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-244.09MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
895.00KUSDFY2025 · Dec 31, 2025Deferred Taxes (CF)
43.24MUSDFY2025 · Dec 31, 2025Stock-based Compensation
37.64MUSDFY2025 · Dec 31, 2025Other Non-cash Items
2.81MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
0.00USDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-15.78MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
975.00KUSDFY2025 · Dec 31, 2025Capital Expenditures
-138.00KUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-138.00KUSDFY2025 · Dec 31, 2025Common Stock Repurchase
-139.00KUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-139.00KUSDFY2025 · Dec 31, 2025Shares Outstanding
51.74MSharesUpdated Sep 28, 2026Float Shares
34.81MSharesUpdated Sep 28, 2026Shares Short
8.54MSharesUpdated Sep 28, 2026Short Ratio
25.45daysvs all stocks
Short % of Shares Outstanding
20.05%vs all stocks
% Held by Insiders
22.15%vs all stocks
% Held by Institutions
93.88%vs all stocks
Total Cash (MRQ)
288.19MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
5.61USDUpdated Sep 28, 2026Total Debt (MRQ)
6.99MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0244xvs Biotechnology peers
Current Ratio (MRQ)
25.05xvs Biotechnology peers
Book Value per Share (MRQ)
5.54USDUpdated Sep 28, 2026Total Assets
326.80MUSDvs all stocks (USD)
Total Current Assets
315.19MUSDFY2025 · Dec 31, 2025Total Liabilities
46.33MUSDFY2025 · Dec 31, 2025Total Non-current Assets
11.61MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
5.49MUSDFY2025 · Dec 31, 2025Total Current Liabilities
40.84MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
307.53MUSDFY2025 · Dec 31, 2025Accounts Payable
5.88MUSDFY2025 · Dec 31, 2025Short-term Debt
2.89MUSDFY2025 · Dec 31, 2025Deferred Revenue
2.66MUSDFY2025 · Dec 31, 2025Other Current Liabilities
13.74MUSDFY2025 · Dec 31, 2025Long-term Debt
5.49MUSDFY2025 · Dec 31, 2025Common Stock (Book)
538.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-1.35BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
280.47MUSDvs all stocks (USD)
52-Week Low
7.73USDUpdated Sep 28, 202652-Week High
11.80USDUpdated Sep 28, 202652-Week Change
-15.06%vs all stocks
Beta
-0.3310xvs all stocks
50-Day MA
8.89USDUpdated Sep 28, 2026200-Day MA
9.36USDUpdated Sep 28, 2026Avg 10-Day Volume
540.46KSharesUpdated Sep 28, 2026Avg 30-Day Volume
402.24KSharesUpdated Sep 28, 2026Diluted EPS (TTM)
-0.8200USDUpdated Sep 28, 2026Other Income / Expense
-30.41MUSDFY2025 · Dec 31, 2025Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Current ratio is 25.05×, higher than 95% of its Biotechnology peers (median 5.96×)Significant
Current ratio: 25.05Industry median: 5.96Industry P95: 22.30Peers compared: 258
Structural Tensions
Looks liquid, but the distress score says otherwiseNotable
Current Ratio: 25.05Altman Z-Score: -1.08
Financial Health
Altman Z-Score -1.08: distress zoneCritical
Altman Z-Score: -1.08
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Honz Pharmaceutical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Hua Medicine Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang East-Asia Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
DiaMedica Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Tuoxin Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Eikon Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Kyverna Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Kehua Bio-Engineering Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Jiangxi Synergy Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shaanxi Panlong Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow